Antimonocyte chemoattractant protein-1 gene therapy reduces experimental in-stent restenosis in hypercholesterolemic rabbits and monkeys
- 3 June 2004
- journal article
- Published by Springer Nature in Gene Therapy
- Vol. 11 (16) , 1273-1282
- https://doi.org/10.1038/sj.gt.3302288
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Essential Role of Monocyte Chemoattractant Protein-1 in Development of Restenotic Changes (Neointimal Hyperplasia and Constrictive Remodeling) After Balloon Angioplasty in Hypercholesterolemic RabbitsCirculation, 2002
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002
- New Frontiers in Interventional CardiologyCirculation, 2001
- Sustained Suppression of Neointimal Proliferation by Sirolimus-Eluting StentsCirculation, 2001
- New Anti–Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E–Knockout MiceCirculation, 2001
- Chemokines and diseaseNature Immunology, 2001
- Anti‐monocyte chemoattractant protein‐1 gene therapy inhibits vascular remodeling in rats: blockade of MCP‐1 activity after intramuscular transfer of a mutant gene inhibits vascular remodeling induced by chronic blockade of NO synthesisThe FASEB Journal, 2000
- Interleukin-8 (IL-8) and monocyte chemotactic and activating factor (MCAF/MCP-1), chemokines essentially involved in inflammatory and immune reactionsCytokine & Growth Factor Reviews, 1998
- Patterns and Mechanisms of In-Stent RestenosisCirculation, 1996
- A Dominant Negative Inhibitor Indicates that Monocyte Chemoattractant Protein 1 Functions as a DimerMolecular and Cellular Biology, 1995